Equities

Alkem Laboratories Ltd

Alkem Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)5,583.35
  • Today's Change-23.40 / -0.42%
  • Shares traded108.51k
  • 1 Year change+22.98%
  • Beta0.6204
Data delayed at least 15 minutes, as of Nov 22 2024 10:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Alkem Laboratories Ltd grew revenues 9.21% from 115.99bn to 126.68bn while net income improved 82.47% from 9.84bn to 17.96bn.
Gross margin63.10%
Net profit margin17.01%
Operating margin17.02%
Return on assets13.49%
Return on equity19.89%
Return on investment18.66%
More ▼

Cash flow in INRView more

In 2024, cash reserves at Alkem Laboratories Ltd fell by 2.07bn. However, the company earned 19.48bn from its operations for a Cash Flow Margin of 15.38%. In addition the company used 10.09bn on investing activities and also paid 11.45bn in financing cash flows.
Cash flow per share206.87
Price/Cash flow per share27.09
Book value per share961.22
Tangible book value per share916.28
More ▼

Balance sheet in INRView more

Alkem Laboratories Ltd has a Debt to Total Capital ratio of 11.04%, a higher figure than the previous year's 1.84%.
Current ratio2.66
Quick ratio1.97
Total debt/total equity0.1286
Total debt/total capital0.1104
More ▼

Growth rates in INR

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 60.00% and 82.47%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)0.91%
Div growth rate (5 year)20.11%
Payout ratio (TTM)2.82%
EPS growth(5 years)18.75
EPS (TTM) vs
TTM 1 year ago
48.12
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.